High-Risk Myelodysplastic Syndrome (STIMULUS-MDS1)
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
|This Study Is Recruiting: Phase II
||Actual Start Date: [June 4, 2019]||Estimated Completion Date: [August 14, 2023]||Novartis Reference Number: CMBG453B12201|
|Condition: High-Risk MDS||Interventions: MBG453, decitabine, azacitidine, placebo||Estimated Enrollment: [120 participants]||ClinicalTrials.gov Identifier: NCT03946670|
|This Study Is: Phase II||Actual Start Date: [June 4, 2019]|
|Estimated Completion Date: [August 14, 2023]||Novartis Reference Number: CMBG453B12201|
|Condition: High-Risk MDS||Interventions: MBG453, decitabine, azacitidine, placebo|
|Estimated Enrollment: [120 participants]||ClinicalTrials.gov Identifier: NCT03946670|
This Phase II is a multicenter, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or decitabine) in adult subjects with IPSS-R intermediate, high or very high risk myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplantation (HSCT) or intensive chemotherapy.
Participants may be eligible to participate if they:
- Are 18 years or older
- Have a confirmed diagnosis of MDS with one of the following prognostic risk categories (per IPSS-R grading system): very high-, high-, or intermediate-risk with ≥5% blasts
- Are not suitable for intensive chemotherapy
- Have no planned hematopoietic stem cell transplantation
- Meet other eligibility criteria
Find a Trial Site Location
To find a list of all our recruiting site locations, enter your address below.
Still Have a Question?
Are you a Patient or Caregiver looking for more information?
Are you a Health Care Professional looking for more information?
To view eligibility requirements for this trial, arms and interventions, trial sites and study design, please click to visit this trial on www.clinicaltrials.gov.
HSCT - hematopoietic stem cell transplantation, ICF - informed consent form, IPSS-R - Revised International Prognostic Scoring System, MDS - myelodysplastic syndrome
Last Updated: July 31, 2019